J 2025

BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview

GEDEONOVA, Dominika; Claretta BIANCHI; Jan STEMBIREK; Matous HRDINKA; Zuzana CHYRA et. al.

Základní údaje

Originální název

BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview

Autoři

GEDEONOVA, Dominika; Claretta BIANCHI; Jan STEMBIREK; Matous HRDINKA; Zuzana CHYRA; Marcela BUCHTOVÁ (203 Česká republika, domácí); Pavel HURNIK; Tomas BLAZEK a Jana REZNAROVA

Vydání

Frontiers in Oncology, Laussane, Frontiers Media SA, 2025, 2234-943X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.500 v roce 2023

Organizační jednotka

Přírodovědecká fakulta

UT WoS

001463362700001

EID Scopus

2-s2.0-105002227069

Klíčová slova anglicky

BRCA1; BRCA2; OSCC (oral squamous cell carcinoma); HNSCC (head and neck squamous cell carcinoma); gene alteration

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 9. 5. 2025 11:11, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Oral squamous cell carcinoma (OSCC), a subset of head and neck cancers, primarily originates in the epithelial tissues of the oral cavity. Despite advancements in treatment, the mortality rate for OSCC remains around 50%, underscoring the urgent need for improved prognostic markers. This review explores the role of the BRCA1 and BRCA2 genes—traditionally associated with breast and ovarian cancers—in the context of OSCC. We discuss the molecular pathways involving BRCA genes, their potential as diagnostics and prognostic biomarkers, and their implications for personalized treatment strategies, including addressing chemotherapy resistance. Furthermore, this review emphasizes the significance of genome stability in cancer progression and examines both current and emerging methodologies for detecting BRCA mutations in OSCC patients. Despite limited prevalence of BRCA mutations in OSCC compared to other cancers, their role in DNA repair and therapeutic response underscores their potential as clinical biomarkers. However, standardized, multicenter studies are still needed to validate their utility in OSCC management. A better understanding of the role of BRCA genes in OSCC could pave the way for more effective therapeutic approaches and improved patient outcomes.